



Hawaii Biotech, Inc.

FOR IMMEDIATE RELEASE

Contact: Dr. Elliot Parks, Hawaii Biotech, Inc., 808-792-1399 eparks@hibiotech.com

HAWAII BIOTECH AWARDED \$38.5 MILLION FOR CONTINUED DEVELOPMENT OF ANTI-TOXIN DRUG TO TREAT ANTHRAX IN HUMANS

(Honolulu, Oct. 30, 2018) -- Hawaii Biotech Inc. will continue its development of an anti-toxin drug for anthrax in humans with a recently awarded contract from the National Institute of Allergy and Infectious Diseases (NIAID), a federal government agency. The maximum value of the contract over five years is \$38,525,879, if all options are awarded.

This contract will support additional pre-clinical development and human clinical testing of a small molecule drug for the treatment of anthrax intoxication following exposure to anthrax lethal factor. Hawaii Biotech will be the prime contractor and conduct work at its facilities in Honolulu and at various sub-contractors.

"Hawaii Biotech has become a trusted partner for the U.S. government's health and defense agencies, and we are committed to continuing our development of anti-terrorism drugs that will protect servicemen and women, as well as all U.S. residents," said Dr. Elliot Parks, chief executive officer of Hawaii Biotech.

"This award from the National Institute of Allergy and Infectious Diseases recognizes Hawaii Biotech's outstanding advancements and achievements in biomedical research. This award is a great step forward to help protect the people of Hawaii, including our military personnel, against biological attacks. I will continue to support medical research and scientific advancements that benefit our state and that contribute to our country's national security and military readiness," said U.S. Senator Mazie Hirono.

NIAID initially awarded the Base period totaling \$7,165,597 and Option 1 totaling an additional \$4,958,949.

This project is funded in whole with federal funds from NIAID, under Contract # HHSN272201800023C. NIAID is part of the National Institutes of Health, which is a division of the U.S. Department of Health and Human Services.

About Hawaii Biotech, Inc.

Hawaii Biotech (HBI) is a privately held biotechnology company focused on the development of prophylactic vaccines for established and emerging infectious diseases and anti-toxin drugs for biological threats. HBI has developed proprietary expertise in the production of recombinant proteins that have application to the manufacture of safe and effective vaccines, diagnostic kits, and as research tools. HBI completed successful first-in-human Phase 1 clinical studies with both West Nile virus and dengue vaccines in healthy human subjects. HBI has developed a product pipeline of recombinant subunit vaccine candidates, including vaccine candidates for West Nile virus, tick-borne flavivirus, malaria, Crimean-Congo hemorrhagic fever, and Ebola. The company is also continuing the development of small molecule anti-toxin drug candidates for anthrax and botulism. Founded in Hawaii in 1982, HBI is headquartered in Honolulu. For more information, please visit: www.hibiotech.com